{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-8.45","upperLimit":"35.39","value":"20.55"},{"groupId":"OG001","lowerLimit":"24.43","upperLimit":"41.88","value":"35.56"},{"groupId":"OG002","lowerLimit":"28.02","upperLimit":"62.79","value":"39.72"},{"groupId":"OG003","lowerLimit":"36.46","upperLimit":"66.32","value":"47.69"},{"groupId":"OG004","lowerLimit":"42.73","upperLimit":"80.38","value":"61.56"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase is calculated as follow: (SFcfb) = 100 × (SFB - SFM) ÷ SFB where SFB is the average weekly seizure frequency in the Baseline phase and SFM is the average weekly seizure frequency in the maintenance period of the Core phase. A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.","dispersionType":"95% Confidence Interval","groups":[{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: \\<3 ng/mL","id":"OG000","title":"<3 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase:3 - 7 ng/mL","id":"OG001","title":"3-7 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: \\>7 - \\<9 ng/mL","id":"OG002","title":">7-<9 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: 9 - 15 ng/mL","id":"OG003","title":"9-15 ng/mL"},{"description":"Observed TN-Cmin concentration during the maintenance of the core phase: \\>15 ng/mL","id":"OG004","title":">15 ng/mL"}],"paramType":"MEDIAN","populationDescription":"Confirmed PK Sample Set from all everolimus-treated patients in the Safety Set was defined as: Cmin collected prior to dose administration on the same treatment day and 20-28 hours after the previous dose, at steady state, and with no evidence of vomiting within 4 hours of the previous dose.","reportingStatus":"POSTED","timeFrame":"Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)","title":"Core Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration","type":"SECONDARY","unitOfMeasure":"Percentage change"}